Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.6% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 4.6% on Monday . The company traded as low as $8.62 and last traded at $8.85. 15,164,269 shares changed hands during trading, a decline of 41% from the average session volume of 25,553,969 shares. The stock had previously closed at $9.28.

Analysts Set New Price Targets

RXRX has been the topic of a number of recent research reports. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.

Recursion Pharmaceuticals Stock Performance

The business’s 50-day simple moving average is $7.56 and its two-hundred day simple moving average is $7.03. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of -5.81 and a beta of 0.86.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at $26,000. Private Trust Co. NA purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth $27,000. GAMMA Investing LLC raised its position in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares during the period. Finally, Farther Finance Advisors LLC increased its stake in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.